Off-label use of recombinant activated factor VII increases risk of arterial events

Off-label use of recombinant activated factor VII (rFVIIa) increases the risk of arterial but not venous thromboembolic events, particularly in older patients, according to an analysis of randomized clinical trials in the New England Journal of Medicine. Read more here.

LEAVE A REPLY

Please enter your comment!
Please enter your name here